Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of anlotinib + liposomal irinotecan + temozolomide after first-line failure in Ewing sarcoma and rhabdomyosarcoma
ChiCTR2500103078Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- May 2025
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, temozolomide and nanoliposomal irinotecan in Ewing sarcoma, embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
anlotinibtemozolomidenanoliposomal irinotecan
03
Conditions
Ewing sarcomaembryonal rhabdomyosarcoma (ERMS)alveolar rhabdomyosarcoma (ARMS)
Beyond the preview
Go deeper on ChiCTR2500103078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103078.